NEW YORK (TheStreet) -- Hello, 2014! Before we crack open the new year, let's close the books on what was a very big 2013 in biotech investing.
In a year where the markets outperformed, the biotech sector performed even better, posting returns not seen since 1999. Phenomenal. No wonder we saw a huge influx of generalist investors into healthcare stocks in 2013.
I'm a skeptic and always nagging readers about risk, so you know I have to point out something for biotech investors to worry about.
Biotech stocks rallied in December but the significant selling in October could not be overcome.
The rest of the Top 10:
Chelsea Therapeutics (CHTP) 484%
Inovio Pharma (INO - Get Report) 481%
Puma Biotech (PBYI) 452%
Acadia Pharma (ACAD - Get Report) 437%
BioCryst Pharma (BCRX) 435%
Idera Pharma (IDRA)420%
Arrowhead Research (ARWR) 407%
Gentium (GENT) 403%
Insys Therapeutics (INSY) 400%
A single biotech and drug stock (Lannett) posted a six-fold bump in share price this year. Nine stocks increased in value by five times, 3 stocks quadrupled in value and 26 stocks tripled in value, according to S&P CapitalIQ.
Not all biotech and drug stocks fared so well in 2013: The biggest losers were:
Enjoy New Year's Day. Tomorrow, we'll get started covering biotech 2014.